[go: up one dir, main page]

AR053650A1 - SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE - Google Patents

SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE

Info

Publication number
AR053650A1
AR053650A1 ARP050104580A ARP050104580A AR053650A1 AR 053650 A1 AR053650 A1 AR 053650A1 AR P050104580 A ARP050104580 A AR P050104580A AR P050104580 A ARP050104580 A AR P050104580A AR 053650 A1 AR053650 A1 AR 053650A1
Authority
AR
Argentina
Prior art keywords
dosage forms
solid oral
estradiol
oral dosage
forms containing
Prior art date
Application number
ARP050104580A
Other languages
Spanish (es)
Inventor
Torsten Wagner
Adrian Funke
Christian Zurth
Kristina Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR053650A1 publication Critical patent/AR053650A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Formas de dosificacion oral solidas que contienen una dosis muy baja de estradiol. Las formas de dosificacion se formulan de modo tal que se evita la degradacion del estradiol y se minimiza el contenido de polivinilpirrolidona, al tiempo que aun se logra una disolucion rápida similar del estradiol. Las formas de dosificacion son utiles para prevenir o tratar una condicion física en una mujer, provocada por niveles endogenos insuficientes de estradiol.Solid oral dosage forms that contain a very low dose of estradiol. The dosage forms are formulated in such a way that degradation of estradiol is avoided and the polyvinylpyrrolidone content is minimized, while still achieving a similar rapid dissolution of estradiol. Dosage forms are useful for preventing or treating a physical condition in a woman, caused by insufficient endogenous levels of estradiol.

ARP050104580A 2004-11-02 2005-11-02 SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE AR053650A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
AR053650A1 true AR053650A1 (en) 2007-05-16

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104580A AR053650A1 (en) 2004-11-02 2005-11-02 SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE

Country Status (21)

Country Link
EP (1) EP1814526A2 (en)
JP (1) JP2008518895A (en)
KR (1) KR20070085558A (en)
CN (1) CN101094656A (en)
AR (1) AR053650A1 (en)
AU (1) AU2005300658A1 (en)
BR (1) BRPI0517940A (en)
CA (1) CA2585095A1 (en)
CR (1) CR9112A (en)
CU (1) CU20070094A7 (en)
EA (1) EA013262B1 (en)
GT (1) GT200500315A (en)
IL (1) IL182635A0 (en)
MX (1) MX2007005281A (en)
NO (1) NO20072704L (en)
PA (1) PA8651401A1 (en)
PE (1) PE20061126A1 (en)
TW (1) TW200621312A (en)
UY (1) UY29185A1 (en)
WO (1) WO2006048261A2 (en)
ZA (1) ZA200705012B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047957A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Pharmaceutical composition for the treatment and prevention of hypertension
DE102009007771B4 (en) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Buccal administration system containing 17α-estradiol
WO2011128336A1 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Very low-dosed solid oral dosage forms for hrt
JP5852639B2 (en) 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Low dose solid oral dosage form for HRT
CN112516149B (en) * 2020-07-21 2023-07-18 南方医科大学 Application of estradiol benzoate or its pharmaceutically acceptable salt in the preparation of anti-coronavirus medicine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125069C (en) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (en) * 1995-10-05 1997-11-28 Innothera Lab Sa UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
FR2754179B1 (en) * 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US7498303B2 (en) * 2000-10-30 2009-03-03 University Of Zuerich GNRH analogues for treatment of urinary incontinence
DK1343508T3 (en) * 2000-12-15 2012-02-27 Novo Nordisk Femcare Ag Use of an estrogen for the manufacture of a composition containing estrogen for the treatment of atrophic vaginitis
FR2823976A1 (en) * 2001-04-25 2002-10-31 Theramex NOVEL HORMONAL COMPOSITION AND ITS USE
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (en) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd Oral composition for prevention and treatment of menopause

Also Published As

Publication number Publication date
UY29185A1 (en) 2006-05-31
CN101094656A (en) 2007-12-26
IL182635A0 (en) 2007-07-24
CR9112A (en) 2007-11-23
EA013262B1 (en) 2010-04-30
EA200700979A1 (en) 2007-10-26
PA8651401A1 (en) 2006-12-07
JP2008518895A (en) 2008-06-05
CU20070094A7 (en) 2009-09-08
WO2006048261A3 (en) 2006-09-21
NO20072704L (en) 2007-05-29
BRPI0517940A (en) 2008-10-21
KR20070085558A (en) 2007-08-27
MX2007005281A (en) 2008-03-11
CA2585095A1 (en) 2006-05-11
TW200621312A (en) 2006-07-01
EP1814526A2 (en) 2007-08-08
AU2005300658A1 (en) 2006-05-11
GT200500315A (en) 2006-06-06
WO2006048261A2 (en) 2006-05-11
PE20061126A1 (en) 2006-11-11
ZA200705012B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
AR046510A1 (en) COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
AR055095A1 (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
AR077573A2 (en) USE OF A TNF INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
CU23821A3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIFFENILUREA REPLACED WITH OMEGA-CARBOXIARIL FOR THE TREATMENT OF CANCER
DK1411932T3 (en) Combination therapy with substituted oxazolidinones
ECSP066959A (en) MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
AR060836A1 (en) A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED
PL375621A1 (en) Pharmaceutical compositions containing flavonoids and menthol
ES2557988T3 (en) Method to treat prostate diseases based on the local supply of active ingredients
CR9112A (en) SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE
ECSP066378A (en) "AN ISOXAZOLINE DERIVATIVE AS AN INHIBITOR AGAINST VARIOUS CASPASES, A PROCEDURE TO PREPARE THE SAME AND A THERAPEUTIC COMPOSITION TO PREVENT INFLAMMATION AND THE APOTOSIS THAT UNDERSTANDS HIMSELF"
ECSP066553A (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED.
UY28154A1 (en) ORAL CARE COMPOSITIONS AND METHODS
PE20070333A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AGOMELATIN FOR THE TREATMENT OF SLEEP DISORDERS IN DEPRESSED PATIENTS
ECSP066805A (en) SILINAN COMPOUNDS AS INHIBITORS OF CYSTEINE PROTEASA
ECSP066685A (en) COMPOSITION THAT INCLUDES A WATER EXTRACT OF RED VINE LEAVES AND AN AGENT THAT IMPROVES THE BLOOD CIRCULATION FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCIES
AR043013A1 (en) PHARMACEUTICAL COMPOSITION INTENDED FOR THE TREATMENT OF ENDOMETRIOSIS
AR039977A1 (en) DICLOFENAC BASED COMPOSITION FOR THE TOPICAL TREATMENT OF OROPHARINGEA CAVITY AFFECTIONS
CR9074A (en) AGENT FOR THE PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME
BRPI0519006A2 (en) use of a fbpase inhibitor, kit of a pharmaceutical composition, use of a biguanide preparation and a fbpase inhibitor, therapeutic agent for diabetes mellitus, and combination of therapeutic agents
AR048355A1 (en) ASSOCIATION BETWEEN A HETEROCICLICAL COMPOUND AND AN ANTIOXIDANT AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR037981A1 (en) USE OF MELOXICAM IN COMBINATION WITH AN ANTIPLAQUETARY AGENT FOR THE TREATMENT OF THE ACUTE CORONARY SYNDROME AND RELATED CONDITIONS
AR029718A1 (en) PHARMACEUTICAL COMPOSITION BASED ON COCAETHYLENE AND ITS USE FOR THE TREATMENT OF THE DEPENDENCY OF PSYCHOACTIVE SUBSTANCES
AR057161A1 (en) METHODS AND DOSAGE FORMS OF BENZISOXAZOL DERIVATIVES WITH BETTER EFFECTIVENESS

Legal Events

Date Code Title Description
FB Suspension of granting procedure